Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

H&R Block (NYSE:HRB) reported a wider-than-expected loss for the second quarter of fiscal 2024, missing analysts' forecasts. The company's stock fell 2.49% in after-hours trading following the ...